A detailed history of Nuveen Asset Management, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 228,385 shares of VRDN stock, worth $4.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
228,385
Previous 498,403 54.18%
Holding current value
$4.52 Million
Previous $6.48 Million 19.88%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.16 - $23.33 $3.28 Million - $6.3 Million
-270,018 Reduced 54.18%
228,385 $5.2 Million
Q2 2024

Aug 09, 2024

SELL
$11.6 - $17.26 $9.67 Million - $14.4 Million
-834,051 Reduced 62.6%
498,403 $6.48 Million
Q1 2024

May 13, 2024

BUY
$17.09 - $23.82 $18.8 Million - $26.2 Million
1,098,574 Added 469.72%
1,332,454 $23.3 Million
Q4 2023

Feb 14, 2024

BUY
$11.12 - $22.5 $338,481 - $684,877
30,439 Added 14.96%
233,880 $5.09 Million
Q3 2023

Nov 14, 2023

SELL
$15.16 - $24.7 $3.38 Million - $5.5 Million
-222,754 Reduced 52.27%
203,441 $3.12 Million
Q2 2023

Aug 14, 2023

SELL
$22.57 - $29.67 $3.42 Million - $4.49 Million
-151,432 Reduced 26.22%
426,195 $10.1 Million
Q1 2023

May 15, 2023

BUY
$25.04 - $37.6 $6.41 Million - $9.63 Million
256,161 Added 79.69%
577,627 $14.7 Million
Q4 2022

Feb 14, 2023

BUY
$18.78 - $29.74 $4.11 Million - $6.5 Million
218,717 Added 212.87%
321,466 $10.9 Million
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $469,023 - $1.12 Million
43,834 Added 74.4%
102,749 $2.05 Million
Q2 2022

Aug 15, 2022

BUY
$9.55 - $19.0 $562,638 - $1.12 Million
58,915 New
58,915 $681,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $789M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.